2-[(4-氨基甲酰基苯基)氨基]乙酸乙酯 | 1021100-40-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 2-[(4-氨基甲酰基苯基)氨基]乙酸乙酯
• 英文名称: ethyl 2-[(4-carbamoylphenyl)amino]acetate
• 英文别名: Ethyl (4-carbamoylphenyl)glycinate；ethyl 2-(4-carbamoylanilino)acetate
• CAS: 1021100-40-2
• 化学式: C₁₁H₁₄N₂O₃
• mdl: MFCD00455058
• 分子量: 222.244
• InChiKey: FECDRGNJNCNXII-UHFFFAOYSA-N

物化性质

• 沸点：
  395.1±22.0 °C(Predicted)
• 密度：
  1.230±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.272
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[(4-氨基甲酰基苯基)氨基]乙酸乙酯 在 potassium carbonate 作用下， 以 溶剂黄146 、 N,N-二甲基甲酰胺 为溶剂， 反应 33.0h， 生成 methyl 6-[[3-(4-carbamoylphenyl)-2,5-dioxo-imidazolidin-1-yl]methyl]-7-methyl-pyrrolo[2,3-d]pyrimidine-2-carboxylate
  参考文献：
  名称：

  Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin

  摘要：

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.02.002

文献信息

• [EN] PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS<br/>[FR] PROMEDICAMENTS DE DERIVES D'IMIDAZOLE SERVANT D'INHIBITEURS DE POMPE A PROTONS DANS LE TRAITEMENT DE L'ULCERE GASTRO-DUODENAL
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2003105845A1

  公开（公告）日：2003-12-24

  An imidazole compound represented by the formula (I), a salt thereof and a compound of the formula (V), which is one of the intermediates thereof. wherein each symbol is as defined in the present specification. The compound of the present invention shows a superior anti-ulcer activity, a gastric acid secretion inhibitory action, a mucosa-protecting action, an anti-Helicobacter pylori action and the like. Since it shows low toxicity, the compound is useful as a pharmaceutical product.

  一种以化学式(I)表示的咪唑化合物，其盐以及化学式(V)的化合物，后者是其中的一种中间体。其中，每个符号如本说明书中所定义。本发明的化合物表现出优越的抗溃疡活性、抑制胃酸分泌作用、保护粘膜作用、抗幽门螺杆菌作用等。由于其低毒性，该化合物可用作药物产品。
• PRODRUGS OF IMIDAZOLE DERIVATIVES, FOR USE AS PROTON PUMP INHIBITORS IN THE TREATMENT OF E.G. PEPTIC ULCERS
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1513527A1

  公开（公告）日：2005-03-16
• CONTROLLED RELEASE PREPARATION
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1553929A2

  公开（公告）日：2005-07-20
• [EN] CONTROLLED RELEASE PREPARATION<br/>[FR] PREPARATION A LIBERATION CONTROLEE
  申请人：TAKEDA CHEMICAL INDUSTRIES LTD

  公开号：WO2004035020A2

  公开（公告）日：2004-04-29

  A controlled release preparation wherein the release of active ingredient is controlled, which releases an active ingredient for an extended period of time by staying or slowly migrating in the gastrointestinal tract, is provided by means such as capsulating a tablet, granule or fine granule wherein the release of active ingredient is controlled and a gel-forming polymer. Said tablet, granule or fine granule has a release-controlled coating-layer formed on a core particle containing an active ingredient.
• Pyrrolopyrimidine-inhibitors with hydantoin moiety as spacer can explore P4/S4 interaction on plasmin
  作者：Naoki Teno、Keigo Gohda、Keiko Wanaka、Yuko Tsuda、Takuya Sueda、Yukiko Yamashita、Tadamune Otsubo

  DOI：10.1016/j.bmc.2014.02.002

  日期：2014.4

  In the development of plasmin inhibitors, a novel chemotype, pyrrolopyrimidine scaffold possessing two motifs, a hydantoin-containing P4 moiety and a warhead-containing P1 moiety, is uncovered. A unique feature of the new line of the plasmin inhibitors is that the interaction between the plasmin inhibitors and key subsites in plasmin can be controlled by a spacer like hydantoin. The application of the novel chemotype is demonstrated by 1n and provides further evidence on the importance of hydantoin as the spacer. (c) 2014 Elsevier Ltd. All rights reserved.